Laser Vaporization of the Prostate: Comparing Between Ejaculatory Preserving and Non-ejaculatory Preserving Technique

Launched by AIN SHAMS UNIVERSITY · Oct 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two different techniques for treating benign prostatic hyperplasia (BPH), a condition where the prostate gland becomes enlarged, causing problems with urination. The trial is comparing a traditional laser surgery method with a new approach that aims to preserve the ability to ejaculate. This is important for men who want to maintain their sexual function while addressing their urinary issues.

To join the trial, participants need to be men over 45 years old who have been diagnosed with urinary problems related to an enlarged prostate and have a specific score indicating their symptoms. They should also have a prostate size of less than 80 grams and a healthy sexual life with the ability to ejaculate. If eligible, participants can expect to undergo one of these two surgical techniques and be monitored for their outcomes. It’s worth noting that men with certain medical conditions or those who have had prostate cancer are not eligible to participate. Overall, this trial aims to find out which technique provides better results, especially regarding the preservation of ejaculation.

Gender

MALE

Eligibility criteria

• Inclusion criteria:
• • Age \>45 years old, clinical diagnosis of BOO by medical history and physical examination (including digital rectal examination)
• • International prostate symptoms score (IPSS) \>14 points
• • Normal PSA (PSA\<4 ng / ml or free/ total PSA \>0.25)
• • Prostate size \< 80 gm
• • Men with recurrent urinary retention (drug-refractory), urinary infection, or haematuria who had failed standard medical therapy (alpha-blockers, 5-alpha reductive inhibitors)
• • Patients were also required to have an active and healthy sexual life, the ability to ejaculate and a desire to preserve ejaculation
• • Exclusion criteria
• • Major psychiatric and somatic diseases and the use of drugs that affect sexual function
• • Patients with ejaculatory dysfunction or no ejaculation
• • Patients with documented or suspected prostate cancer
• • Patients with neurogenic bladder, voiding dysfunction, urethral strictures, and malignancies of the upper or lower urinary tract,
• • Prostates sized more than 80 CC, severe comorbidities or high surgical risk patients.